Panasonic Connect Named Honeywell Authorized Distributor, Bringing More Choice to Customers
NEWARK, N.J.--(BUSINESS WIRE)-- Panasonic Connect North America, Division of Panasonic Corporation of North America, announced its designation as an authorized distributor of Honeywell Android Products, including its rugged handhelds and tablet. The partnership simplifies the buying process for mission critical professionals across public sector, healthcare, utilities, and government seeking high-quality, reliable, and secure devices that can withstand the toughest environments.
The products accompany Panasonic Connect's industry-leading portfolio of TOUGHBOOK ® laptops and 2-in-1 computers, including the TOUGHBOOK 40, TOUGHBOOK 55, TOUGHBOOK 33 and TOUGHBOOK G2, bringing customers even greater flexibility. Whether benefiting from the Android devices as standalone edge products or as a companion device with TOUGHBOOK solutions, customers can now source what they need from a single partner.
'Panasonic Connect has long been a trusted technology provider for rugged mobility and frontline workers,' said Dominick Passanante, Senior Vice President & General Manager for the Mobility Business at Panasonic Connect North America. 'We continue to refine our position as a one-stop consultative shop for rugged mobile solutions and for supporting successful digital transformations in mission-critical industries. This partnership reflects our shared commitment to understanding and addressing the unique needs of our customers, ensuring that our offerings provide maximum value and support.'
The Android devices from Honeywell that will now be available through Panasonic Connect include the Honeywell CT37 (a mobile Android handheld), Honeywell CT47 (a rugged, all-purpose Android handheld), and Honeywell RT10A (a rugged Android tablet). These products support Panasonic Connect in giving customers access to productivity tools that improve visual data capture, asset tracking and management, and connectivity and communication across operations. For more product information, visit https://connect.na.panasonic.com/android.
'Honeywell Productivity Solutions and Services (PSS) is delighted to embark upon this new partnership with Panasonic Connect that enables us to be stronger together to serve customers in these business-critical segments. Honeywell PSS and Panasonic Connect share a rugged heritage and highly symbiotic cultures enabling the success of our customers' productivity goals. I am excited for what the future brings as we combine our proven Android enterprise devices with Panasonic Connect's TOUGHBOOK,' said Georgina Lamb, Vice President & General Manager, US and Canada at Honeywell PSS.
About Panasonic Connect North America
Established on April 1, 2022, as part of the Panasonic Group 's switch to an operating company system, Panasonic Connect North America is a B2B company offering device hardware, software and professional services to provide value to customers across the public sector, federal government, education, immersive entertainment, food services and manufacturing industries. With the mission to 'Change Work, Advance Society, Connect to Tomorrow,' Panasonic Connect North America works closely with its community of partners, innovators and integrators to provide the right technologies to address customers' ever-evolving needs in today's connected enterprise.
About Honeywell
Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter, safer and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
43 minutes ago
- Yahoo
Milwaukee County small business development program approved
The Brief Milwaukee County has a new small business development program. County Executive David Crowley signed legislation on Wednesday, June 11 to approve the new Building Bridges program. The program will create a new small business liaison position to provide technical support and administer $10,000 grants to small businesses across Milwaukee County. WEST ALLIS, Wis. - Milwaukee County Executive David Crowley signed legislation on Wednesday, June 11 at West Allis City Hall approving the new Building Bridges small business development and commercial corridor activation program. What we know A news release from the county says the Building Bridges program will create a new small business liaison position to provide technical support and administer $10,000 grants to small businesses across Milwaukee County. The goal is to expand resources to establish or expand brick-and-mortar businesses in Milwaukee County while fueling commercial corridor revitalization. Milwaukee County Economic Development was recently awarded $200,000 from the Wisconsin Economic Development Corporation (WEDC) for this program, which will be used to provide $10,000 grants to qualifying small businesses. What they're saying "During my State of the County address, I called on my administration to build bridges between small businesses, entrepreneurs, small business support organizations, and municipalities seeking to fill commercial corridor spaces. Because through partnership, we know we can fuel local economic development," said County Executive Crowley. "Under my direction, Milwaukee County is taking a stronger approach to supporting small businesses, growing our economy, and creating job opportunities for workers. Thank you to WEDC and all of our partners for making this new effort a reality that will help build wealth, strengthen our neighborhoods, and uplift small businesses across Milwaukee County." FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android "Small businesses are the heart of our communities and downtowns," said Missy Hughes, secretary and CEO of the Wisconsin Economic Development Corporation. "The Building Bridges program is a great example of how partnerships between small businesses, communities, and other organizations can work together to create an environment where everyone has the opportunity to thrive and our economy grows." Dig deeper During Wednesday's legislation signing ceremony, Crowley announced the first grant recipient of the Building Bridges program. The grant recipient is All Goods, a vintage clothing store based in Milwaukee County, that specializes in curated vintage apparel. Ali Acevado, the owner of All Goods, purchased and is renovating an old, vacant laundromat on Greenfield Avenue in the City of West Allis, where he will move his business in the coming months. SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News The City of West Allis is supporting the project with a low-interest loan. The Building Bridges grant will be used for the building's renovations, including structural and foundation work, electrical, plumbing, and more. The Building Bridges program includes accepting grant applications from small businesses, administering grants following approval, and hiring a small business liaison to carry out this work. The Source The information in this post was provided by Milwaukee County.
Time Business News
an hour ago
- Time Business News
DooFlix APK Download Latest Version For Android 2025
DooFlix APK is a popular streaming application that allows users to watch a wide range of movies, TV shows, documentaries, and web series directly on their Android devices. Designed with a user-friendly interface, DooFlix offers a seamless viewing experience without the need for complicated subscriptions or sign-ups. Whether you're a fan of Hollywood blockbusters, Bollywood hits, or international cinema, DooFlix provides a diverse content library that caters to all tastes. One of the key features of DooFlix is its regularly updated database, ensuring that users always have access to the latest releases. The app supports HD and Full HD streaming, with the option to adjust video quality based on internet speed. Additionally, users can download content to watch offline, making it convenient for travel or areas with limited connectivity. DooFlix APK also includes multiple server options, helping ensure stable playback even during peak times. With built-in subtitles and support for multiple languages, it caters to a global audience. The app's intuitive layout, categorized content, and search functionality make it easy to find and enjoy your favorite titles quickly. Another major advantage of DooFlix APK is that it is free to use. Unlike many mainstream platforms, there are no subscription fees or hidden costs. However, as it is a third-party app, it is not available on the Google Play Store and must be downloaded via an APK file from trusted sources. Overall, DooFlix APK is an excellent choice for movie and series enthusiasts looking for a flexible, cost-effective, and content-rich streaming solution. With its powerful features and accessibility, it continues to grow in popularity among Android users worldwide. Features OF DooFlix APK Extensive Content Library DooFlix APK boasts a vast collection of content, including movies, TV series, documentaries, and anime from around the world. It covers various genres such as action, comedy, drama, horror, romance, sci-fi, and thriller, catering to a wide range of tastes. Free to Use Unlike most mainstream streaming platforms, DooFlix is completely free. There are no monthly fees, registration requirements, or hidden charges. Users can enjoy unlimited streaming without spending a single penny. High-Quality Streaming The app supports HD, Full HD, and even 4K streaming (where available). It automatically adjusts video quality based on your internet connection or allows you to set it manually for a smooth and buffer-free experience. Offline Viewing DooFlix APK Download offers a download feature that allows users to save their favorite shows and movies directly to their device. This is especially useful for watching content when offline, such as during travel or in areas with poor connectivity. Multiple Language Support The platform includes content in various languages and often provides subtitles in multiple languages as well. This feature helps make international content accessible to a broader audience. User-Friendly Interface DooFlix has a clean, intuitive layout with easy-to-navigate menus, categorized content, and a responsive search function. Even first-time users can browse and watch content without any hassle. Regular Content Updates The app's library is frequently updated with the latest releases, trending titles, and newly added episodes. This ensures users always have fresh content to watch without long waits. Low Storage Requirement Despite offering a wide range of features, DooFlix is a lightweight application. It does not consume much storage or system resources, making it suitable for devices with limited space. No Registration or Login Needed DooFlix values user convenience and privacy. It doesn't require users to create an account or log in, eliminating barriers to access and reducing data sharing concerns. Built-in Video Player The app comes with a built-in video player that supports advanced playback features like fast-forward, subtitles, screen lock, and brightness control, offering a complete in-app viewing experience. Multi-Server Streaming To ensure reliable streaming, DooFlix App offers multiple server options for each title. If one server is slow or down, users can quickly switch to another, minimizing interruptions. Compatibility with Android Devices DooFlix is optimized for a wide range of Android devices including smartphones, tablets, and even Android TV boxes. It works smoothly across various screen sizes and hardware configurations. How To Download Go to Settings > Security and allow installation from unknown sources. Visit a trusted website and download the latest DooFlix v8.6 file. Open your device's File Manager and find the downloaded APK in the Downloads folder. Tap on the APK file to begin the installation process. Allow any required permissions if prompted during installation. Wait for the installation to finish and tap 'Open' once done. For safety, you can turn off installation from unknown sources again. Open DooFlix from your app drawer and start streaming. How to use Launch DooFlix from your device's app drawer. Explore content by categories like Movies, Series, or Trending. Type the title of the movie or show you want to watch. Tap on any title to view its details and streaming options. Pick a server for smoother playback if multiple are available. Hit the play button to start streaming instantly. Use the subtitle option to select your preferred language. Tap the download icon to save content for later viewing. Use the built-in player to control volume, brightness, or screen lock. Tap the heart icon to save titles to your favorites list. Check for updates to get the latest features and content. Use the back button or menu to exit the app when finished. Conclusion TIME BUSINESS NEWS
